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BACKGROUND & AIMS: Gluteofemoral obesity (determined by measurement of 
subcutaneous fat in hip and thigh regions) could reduce risks of cardiovascular and diabetic 
disorders associated with abdominal obesity. We evaluated whether gluteofemoral obesity 
also reduces risk of Barrett’s esophagus (BE), a premalignant lesion associated with 
abdominal obesity. 
 
METHODS: We collected data from non-Hispanic white participants in 8 studies in the 
Barrett’s and Esophageal Adenocarcinoma Consortium. We compared measures of hip 
circumference (as a proxy for gluteofemoral obesity) from cases of BE (n=1559) separately 
with 2 control groups: 2557 population-based controls and 2064 individuals with 
gastroesophageal reflux disease (GERD controls). Study-specific odds ratios (OR) and 95% 
confidence intervals (95% CI) were estimated using individual participant data and 
multivariable logistic regression and combined using random effects meta-analysis. 
 
RESULTS: We found an inverse relationship between hip circumference and BE (OR per 5 
cm increase, 0.88; 95% CI, 0.81–0.96), compared with population-based controls in a 
multivariable model that included waist circumference. This association was not observed in 
models that did not include waist circumference. Similar results were observed in analyses 
stratified by frequency of GERD symptoms. The inverse association with hip circumference 
was only statistically significant among men (vs population-based controls: OR, 0.85; 95% 
CI, 0.76–0.96 for men; OR, 0.93; 95% CI, 0.74–1.16 for women). For men, within each 
category of waist circumference, a larger hip circumference was associated with decreased 
risk of BE. Increasing waist circumference was associated with increased risk of BE in the 
mutually adjusted population-based and GERD control models.  
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CONCLUSIONS: Although abdominal obesity is associated with increased risk of BE, there 
is an inverse association between gluteofemoral obesity and BE—particularly among men. 
 
KEY WORDS: BEACON; Obesity; Esophageal Cancer; Epidemiology; Risk Factors 
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Abdominal obesity is associated with an increased risk of esophageal adenocarcinoma (EA) 
and its precursor lesion Barrett's esophagus (BE).1,2 These associations remain after 
controlling for the confounding effects of gastroesophageal reflux disease (GERD) 
symptoms, suggesting that non-GERD factors are important.3 In abdominal obesity, increased 
intra-abdominal adipose tissue stores may cause a number of systemic effects including 
insulin resistance, alteration in adipokines and cytokines, and systemic chronic 
inflammation.4 These systemic effects have been associated with non-esophageal cancers and 
a recent meta-analysis found they may be important in BE.5 
Abdominal obesity is also strongly associated with an increased risk of diabetes 
mellitus and cardiovascular disease.6 In contrast, gluteofemoral obesity, manifested by 
increased subcutaneous fat in the hip and thigh region, has a protective association with these 
disorders.7,8 One postulated mechanism for this protective effect is that gluteofemoral adipose 
tissue acts as a metabolic "sink" reducing the levels of circulating free fatty acids, insulin and 
adipocytokines that lead to metabolic and cardiovascular disease.9 
 Few studies have examined the effects of gluteofemoral obesity on the risks of EA 
and BE. A large cohort study of 391,456 participants (of whom 124 developed EA during 
follow-up) found that, after mutual adjustment, the risk of EA was strongly positively 
associated with abdominal obesity but inversely associated with gluteofemoral obesity.10 In a 
case-control study of BE, conducted among males referred for colorectal cancer screening, 
there was a suggestion of a similar inverse association with gluteofemoral obesity, although 
the precision of the estimates were limited by study size and sex-specific effects were unable 
to be analyzed as all participants were males.11 
 Investigating the effects of fat distribution patterns on the risk of BE is important in 
furthering our understanding of the role of obesity in BE. If gluteofemoral obesity were found 
to reduce the risks associated with abdominal obesity, this would support the hypothesis that 
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potentially modifiable metabolic factors related to abdominal obesity (but unrelated to 
GERD) are important in the pathogenesis of the disease. In addition, sex differences in fat 
distribution may help explain the large male-predominance seen at each stage of the natural 
history of EA including BE.12-15 
 The international Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON, 
http://beacon.tlvnet.net/) is a large international consortium that has pooled and harmonized 
detailed individual participant data including anthropometric measurements from case-control 
studies of BE. Using this unique resource, this analysis determined the risks of BE associated 
with gluteofemoral and abdominal obesity and assessed the effects of each exposure after 
mutual adjustment. Further, we sought to determine if there were sex differences in these 
associations and whether the associations with gluteofemoral and abdominal obesity were 
confounded or modified by other known risk factors for BE.
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Materials and Methods 
Study population 
BEACON was formed in 2005 in collaboration with the US National Cancer Institute. 
For the purpose of this analysis, we initially pooled individual participant data from 1909 BE 
cases, 3618 population-based controls and 2666 GERD controls from eight independent case-
control studies participating in BEACON (see Supplementary Material)11,16-21. Details of the 
five original case-control studies in BEACON and the data pooling methods for BEACON 
have been described in detail elsewhere.22,23 The remaining three case-control studies were 
recently added to the BEACON dataset, are included in this study, and have been described 
previously.11,20,21 In all studies, cases included persons with endoscopic evidence of columnar 
mucosa in the tubular esophagus, accompanied by the presence of specialized intestinal 
metaplasia in an esophageal biopsy, and cases included persons with prevalent and newly 
diagnosed BE.11,20-22 The cases are compared with population-based controls, that represent 
the underlying source population from which cases arose, and GERD controls, the population 
undergoing endoscopy from which BE cases are diagnosed. Population-based controls were 
frequency matched to BE cases on sex and age in most,16,18,19,21 but not all studies.11,20 GERD 
controls were matched to the BE group on age and sex in only two studies.18,21 The FINBAR 
study matched controls to their EA cases rather than BE cases.17 The original studies and the 
current data pooling were approved by the institutional review board or research ethics 
committee of each sponsoring institution. Written informed consents were obtained from all 
study subjects. 
For the current analysis, we excluded persons with missing data for waist and/or hip 
circumferences (431 population-based controls, 421 GERD controls and 236 BE cases). We 
additionally restricted our analyses to non-Hispanic white study participants (2557 
population-based controls, 2064 GERD controls, 1559 BE cases) due to low numbers of 
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cases from non-white ethnic groups. Seven studies provided a population-based control group 
and six studies provided a GERD control group (Table 1). 
 
Study variables 
At interview, the following anthropometric measures were collected in-person using 
study-specific protocols: height, weight, waist circumference, and hip circumference. In the 
Kaiser Permanente study, measurements of mid-thigh circumference were taken instead of 
hip circumference and used as a proxy for gluteofemoral obesity.18 As detailed below, for the 
analysis, we used study-specific tertiles to overcome the issue of differences in distributions 
between the included studies. Excluding Kaiser Permanente from the analysis did not change 
the results. We calculated body mass index (BMI) as weight in kilograms divided by height 
in meters squared (kg/m2). In addition to the anthropometric data, individual-level 
harmonized clinical, demographic, and questionnaire data for each study participant were 
merged into a single de-identified dataset and included information on study, case-control 
status, age at diagnosis for cases and age at study enrolment for controls, sex, ethnicity, 
highest level of education, frequency of GERD symptoms and history of cigarette smoking. 
Frequency of GERD symptoms was the highest reported frequency of either heartburn or acid 
regurgitation symptoms. We defined “frequent symptoms” as those occurring at least weekly. 
The data were checked for consistency and completeness and any apparent inconsistencies 
were followed-up with individual study investigators. 
 
Statistical analysis 
The primary aim of the analysis was to examine the associations of hip circumference 
and waist circumference (in tertiles and as a continuous measure) with the risk of BE, and 
then the effect of each measure after mutual adjustment with the risk of BE. Because 
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distributions of anthropometric measures varied across studies and sexes, we derived study- 
and sex-specific tertiles for hip and waist circumferences. We used a two-step analytic 
approach.24 In the first stage, study-specific odds ratios (ORs) and 95% confidence intervals 
(CIs) were estimated using unconditional logistic regression models. In the second stage, the 
study-specific ORs were combined using random-effects meta-analytic models to generate 
summary ORs. We excluded studies from the second-step if the logistic regression model 
failed to converge. We used the inconsistency index, I2, to assess heterogeneity between 
studies.25 Larger I2 values reflect increasing heterogeneity, beyond what is attributable to 
chance. I2 values of 25%, 50% and 75% were used as evidence of low, moderate, or high 
levels of heterogeneity, respectively. 
Exposure variables were assessed in relation to risk of BE using population-based 
controls and GERD controls as comparison groups. Our approach was, first, to examine the 
unadjusted associations of hip circumference and waist circumference with risk of BE. We 
then adjusted for age (<50, 50-<60, 60-<70, ≥70 years), sex, education (school only, technical 
college/diploma, university/college; unavailable and so unadjusted for in the University of 
North Carolina at Chapel Hill study), and smoking status (never, ever). Finally, we further 
mutually adjusted for hip and waist circumference to examine their independent effects on 
risk of BE. Models that compared cases with population-based controls were also 
subsequently adjusted for self-reported GERD symptoms (less than weekly vs. at least 
weekly) to evaluate potential confounding effects of GERD symptoms. The study-specific 
ORs for the Cleveland Barrett’s Esophagus Study were unadjusted for education, smoking 
status and GERD symptoms due to unavailable data for these variables among population-
based controls. The lowest tertile for each categorical variable was used as the reference 
category. We evaluated continuous variables to test for linear trend by using OR per 5 cm 
increase in hip and waist circumference. 
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Finally, we assessed whether the association between hip circumference (and waist 
circumference) and risk of BE was modified by sex (male, female) by performing likelihood 
ratio tests of nested models with and without the hip circumference-sex interaction term. 
Likewise, but for comparisons with population-based controls only, we also assessed for 
effect modification by frequency of GERD symptoms (less than weekly, at least weekly). 
All tests for statistical significance were two-sided at α=0.05 and analyses were 
conducted using Stata 13.1 (StataCorp LP, College Station, TX). 
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Results 
The numbers of cases and controls, summary data for anthropometric measurements 
by study, and characteristics of the pooled dataset are shown in Tables 1 and 2. Cases and 
population-based controls were similar in terms of age and sex due to matching in most 
studies. There was considerable variation in average BMI, and waist and hip circumferences 
across the studies and case-control groups. 
 Table 3 shows the estimates of association between waist and hip circumferences and 
BE compared with both population-based controls and GERD controls. After adjusting for 
age, sex, education, and smoking status, waist circumference was positively associated with 
BE for comparisons with population-based controls (summary OR per 5cm increase = 1.08; 
95% CI: 1.01-1.15). After further adjustment for hip circumference, the magnitude of the 
association between waist circumference and BE was strengthened (vs. population-based 
controls: OR = 1.18; 95% CI: 1.06-1.31; Tertile 3 vs. Tertile 1, OR = 2.18; 95% CI: 1.35-
3.51, Ptrend<.001). While the association with waist circumference adjusted for hip 
circumference was somewhat attenuated when we compared cases with GERD controls, 
waist circumference remained statistically significantly associated with increased BE risk 
(OR = 1.09; 95% CI: 1.02-1.16). 
 In contrast, when compared with population-based controls, there was no association 
between hip circumference and BE in the unadjusted model or in the model adjusted for only 
age, sex, education, and smoking status (Table 3). However, after further adjustment for waist 
circumference, we found an inverse association between hip circumference and BE for 
comparisons with population-based controls (OR = 0.88; 95% CI: 0.81-0.96). Compared to 
persons in the lowest tertile of hip circumference, persons in the highest tertile of hip 
circumference had 25% lower risk of BE (95% CI: 0.58-0.98, Ptrend = .04) in the mutually 
adjusted model (Supplementary Figure 1). We found no consistent association between hip 
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circumference and BE when cases were compared with GERD controls (OR = 0.97; 95% CI: 
0.87-1.08). For comparisons with population-based controls, the positive association with 
waist circumference (OR = 1.10; 95% CI: 1.01-1.21) and inverse association with hip 
circumference (OR = 0.89; 95% CI: 0.81-0.97) remained after additional adjustment for 
frequency of GERD symptoms (Supplementary Table 1). 
 When stratified by sex (Table 4), the strength of the association of waist 
circumference with BE was similar in males and females in the mutually adjusted population-
based control model; although risk estimates for females did not reach statistical significant 
perhaps due to small numbers. We found no evidence for statistical interaction between waist 
circumference and sex in relation to risk of BE (Pinteraction = .10). However, hip circumference 
was inversely associated with BE in males in the mutually adjusted population-based control 
model (OR = 0.85; 95% CI: 0.76-0.96) but was not associated with BE in females (OR = 
0.93; 95% CI: 0.74-1.16; Pinteraction = .004). We additionally performed stratified analyses by 
GERD symptom history using the population-based control group as the comparator (Table 
5). Waist circumference appeared to be more strongly associated with BE in those with 
infrequent GERD symptoms. The inverse association between hip circumference and BE was 
similar in magnitude in both those with infrequent and frequent GERD symptoms and 
frequency of GERD symptoms does not appear to modify the inverse association with hip 
circumference (Pinteraction = .62).  
 Among males within each category of waist circumference, larger hip circumference 
was associated with a decreased risk of BE (Supplementary Table 2). Males at the highest 
risk of BE simultaneously had waist circumference in the highest tertile and hip 
circumference in the lowest tertile. Males at the lowest risk of BE had waist circumference in 
the lowest tertile and hip circumference in the highest tertile. The pattern was different for 
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females with hip circumference not reducing the risk of BE within each waist category; 
however, these analyses were limited by smaller numbers of females in all categories. 
 We found evidence for moderate to high between-study heterogeneity for associations 
between waist circumference and BE (Table 3). However, removal of the Cleveland Barrett’s 
Esophagus Study reduced the between-study heterogeneity to below 10%. The association 
with waist circumference was somewhat attenuated as a result (ORTertile 2 = 1.37; 95% CI: 
1.08-1.74; I2 = 9%; ORTertile 3 = 1.68; 95% CI: 1.28-2.22; I2 = 4%). Likewise, there was 
evidence of low to moderate between-study heterogeneity for the association between hip 
circumference (continuous) and risk of BE (Table 3). This heterogeneity was mainly driven 
by a stronger inverse association from The Newly Diagnosed Barrett’s Esophagus Study. 
When this study was excluded, I2 reduced from 42% to 20%. Importantly the effect estimate 
was only minimally attenuated and hip circumference remained inversely associated with BE 
(OR = 0.90; 95% CI: 0.83-0.98) when compared with population-based controls. 
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Discussion 
We conducted pooled analyses of eight case-control studies, examining the 
independent effects of abdominal obesity and gluteofemoral obesity on the risk of BE. As has 
been shown previously, we confirmed that abdominal obesity is associated with increased 
risk of BE. But in addition, we found that gluteofemoral obesity was inversely associated 
with BE. This association was strongest when we compared cases with population-based 
controls, and persisted even after adjusting for frequency of GERD symptoms. Finally, we 
found evidence of modification of the effect of gluteofemoral obesity by sex; the inverse 
association with hip circumference was statistically significant for analyses among males, but 
not in analyses among females. 
 In a prior cohort study, Steffen et al. found that gluteofemoral obesity was inversely 
associated with risk of EA, adjusting for abdominal obesity.10 However, that study was not 
able to adjust for potential confounding by GERD. In a prior case-control study, Rubenstein 
et al. found that gluteofemoral obesity was inversely associated with a combined outcome of 
BE or erosive esophagitis, adjusting for abdominal obesity, but the study was too small to 
accurately estimate the effect on BE alone, and did not include any females.11 Gluteofemoral 
obesity has previously been shown to be protective against diabetes mellitus and 
cardiovascular disease.7,8  
Adipose tissue in the gluteofemoral compartment behaves differently metabolically 
than adipose tissue in the abdominal compartment.7,9,26 It has been hypothesized that 
gluteofemoral adipose tissue may serve as a “metabolic sink” where excess calories can be 
safely stored without detrimental metabolic effects. Our finding of an inverse association of 
gluteofemoral obesity with the risk of BE suggests that abdominal obesity may not only exert 
its effects on risk via mechanical effects in promoting GERD but also via non-GERD 
metabolic effects. Multiple studies have demonstrated an association between levels of 
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different circulating adipokines and BE or EA.5,21,27-29 It seems unlikely that a single factor is 
responsible for all of the risk attributable to obesity; rather it would seem that abdominal 
obesity (if not counteracted by gluteofemoral obesity) results in a milieu of circulating 
metabolic factors that promote BE and EA. Risk prediction models for BE that include a term 
for waist-to-hip ratio have been shown to have reasonable discriminatory ability;30,31 whether 
gluteofemoral (hip circumference) and abdominal (waist circumference) obesity separately 
discriminate better between persons with and without BE than waist-to-hip ratio is unknown 
and requires further study. 
 Importantly, we found evidence for modification of the effect of gluteofemoral 
obesity by sex. There does not appear to be a protective effect among females. For unclear 
reasons, males are at much greater risk than females for BE,12 and especially for EA.32,33 
Females and males differ in their distribution of adipose tissue, with males having over 50% 
greater intra-abdominal fat mass and a third less subcutaneous fat, including gluteofemoral 
fat, than females.34 In addition, estrogen regulates the secretion of adipokines from adipose 
tissue.35 Taken together, these findings suggest that the differential compartments for 
deposition of adipose tissue and metabolic effects may explain much of the risk of male sex 
for BE.  
 Our study had some limitations. First, we were only able to study the outcome of BE 
and not EA. In EA nearly two-thirds of patients have substantial weight loss at diagnosis, 
making the study of obesity related factors difficult in case-control studies.36 In addition, the 
studies included a mix of patients with newly diagnosed and prevalent diagnoses of BE, 
which could have biased the results unpredictably. While we attempted to control for 
confounding, information on some known risk factors for BE (e.g. Helicobacter pylori status, 
diet, medication use) was not uniformly available across the studies, and it is possible that 
unmeasured (and/or unknown) variables might have influenced our results. Whether obesity 
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(gluteofemoral and/or abdominal) affects risk of BE independently of GERD is further 
complicated in observational studies as it is impossible to exclude residual confounding by 
GERD because symptom history is imperfectly correlated with the occurrence of GERD, and 
reporting can be compromised by treatment history. Studies combining genetic and 
observational data are attempting to address this issue.37 We examined associations separately 
in males and females; however, even with the large resources of BEACON, the number of 
females in our study was still small and the risk estimates for females were imprecise as a 
result. Finally, there was moderate heterogeneity in some effect estimates. This between-
study heterogeneity was largely driven by a single study. However, removal of the study only 
minimally attenuated the inverse association with hip circumference and risk of BE. While 
hip circumference was inversely associated with BE among persons with frequent GERD 
symptoms for comparisons with population-based controls, there was no association when we 
compared cases with GERD controls. There was however moderate to high between-study 
heterogeneity for these risk estimates, some of which may be due to differences between the 
individual study inclusion criteria for GERD controls. 
There are also a number of strengths to the study. Notably, we were able to combine 
data from eight independent studies from different geographic regions. The component 
studies used a similar diagnosis of BE, and all measured anthropometrics rather than using 
self-report. We were able to compare the effects to both population controls and GERD 
controls, adjust for a number of important potential confounders, and examine for effect 
modification by sex. 
 In summary, we found that while abdominal obesity is associated with increased  risk 
of BE, gluteofemoral obesity is inversely associated with the risk of BE. The inverse 
association with gluteofemoral obesity is independent of GERD, and may not be present in 
females. These findings support a metabolic explanation for the effect of obesity on BE and 
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for the risk of male sex on BE. Further studies are required to determine whether the 
distribution of obesity and metabolic effects promote the progression from BE to EA, and 
whether modifying these factors can prevent the cancer. 
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Table 1 Distribution of Body Mass Index, Waist Circumference and Hip Circumference by Study 
 
 Population-based controls GERD controls BE cases 
  BMI (kg/m2) Waist (cms) Hip (cms)  BMI (kg/m2) Waist (cms) Hip (cms)  BMI  
(kg/m2) 
Waist (cms) Hip (cms) 
Study n Mean (SD) Mean (SD) Mean (SD) n Mean (SD) Mean (SD) Mean (SD) n Mean (SD) Mean (SD) Mean (SD) 
Houston 273 31.1 (6.2) 112.6 (14.0)   115.7 (12.8) 823 30.1 (5.9) 108.7 (13.7)   113.0 (11.9) 287 30.3 (5.5) 110.9 (13.4)   112.9 (11.2) 
Cleveland 707 27.8 (5.8)   94.5 (16.1)   105.1 (14.3) 115 29.5 (5.8) 105.1 (17.0)   107.2 (15.1) 105 30.8 (5.7) 108.6 (13.4)   109.9 (13.9) 
FINBAR 256 27.7 (4.0)   97.6 (11.2) 102.1 (9.3) 229 29.2 (4.0) 98.0 (9.9) 102.9 (8.4) 224 27.8 (4.4)   99.2 (11.7)   103.1 (10.0) 
KPNC 263 29.5 (5.7)   99.5 (15.7)  251 29.2 (4.9)   98.2 (14.4) a 260 29.5 (5.6) 101.3 (14.7)  
NDB 639 29.8 (5.5) 107.4 (13.6)   107.2 (10.7) 0 - - - 133 30.5 (5.0) 110.0 (12.7) 107.3 (9.2) 
SDH 233 26.8 (4.5)   97.6 (13.3) 106.4 (8.6) 0 - - - 231 27.7 (4.6) 101.6 (12.9) 107.9 (9.5) 
Washington 186 27.7 (5.0)   94.9 (14.2) 107.0 (9.6) 371 28.4 (5.5)   96.5 (13.7)   108.5 (10.9) 171 29.3 (5.1) 100.0 (13.1)   109.5 (10.7) 
UNC 0 - - - 275 28.0 (6.2)   91.4 (16.5)   103.6 (15.0) 148 28.4 (5.8)   97.2 (16.9)   103.9 (14.5) 
NOTE. a KPNC includes thigh measures and not hip circumference: Population controls, 49.9 cms (6.3); GERD controls, 49.1 cms (5.7); BE cases, 49.9 cms (6.9). 
Participating studies: Houston, the Houston Barrett’s Esophagus study; Cleveland, the Cleveland Barrett’s Esophagus Study(Case Comprehensive Cancer Center: 
University Hospitals Case Medical Center and Cleveland Clinic Foundation); FINBAR, the Factors Influencing the Barrett’s/Adenocarcinoma Relationship study 
(Ireland); KPNC, the Epidemiology and Incidence of Barrett’s Esophagus study (Kaiser Permanente, Northern California); NDB, The Newly Diagnosed Barrett’s 
Esophagus Study (University of Michigan and Ann Arbor Veterans Affairs Medical Center, Michigan); SDH, the Study of Digestive Health (Brisbane, Australia); 
Washington, the Study of Reflux Disease (western Washington State); and UNC, the Epidemiologic Case-Control Study of Barrett’s Esophagus (Chapel Hill, North 
Carolina). 
BE, Barrett’s esophagus; BMI, body mass index, GERD, gastroesophageal reflux disease; SD, standard deviation. 
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Table 2 Characteristics of the Combined Study Population within the BEACON Consortium 
 
 
BE cases 
(n = 1559) 
Population-based controls 
(n = 2557)  
GERD controls 
(n = 2064) 
Age, y, mean (SD)  60.0 (11.1) 58.2 (9.9)   57.3 (12.1) 
Male sex, n (%) 1253 (80.4)  1839 (71.9)  1489 (72.1) 
Education, n (%)     
 School only   425 (28.9)   385 (21.1)    620 (37.0) 
 Tech/Diploma   615 (41.7)   764 (41.8)    502 (29.9) 
 University   433 (29.4)   677 (37.1)    555 (33.1) 
 Missing 49 731  113 
Smoking status, n (%)     
 Never   489 (32.2)   760 (41.6)    779 (39.5) 
 Ever 1030 (67.8) 1066 (58.4)  1192 (60.5) 
 Missing 40 731  93 
Frequency of GERD symptoms, n (%)     
 Less than weekly   453 (31.0) 1355 (77.3)    686 (37.0) 
 At least weekly 1009 (69.0)   399 (22.7)  1170 (63.0) 
 Missing 97 803  208 
NOTE. All population-based controls from Cleveland (n=707) were missing data for education, smoking 
status and frequency of GERD symptoms.  
BE, Barrett’s esophagus; GERD, gastroesophageal reflux disease; SD, standard deviation; y, years.
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Table 3 Odds Ratios and 95% Confidence Intervals for the Associations Between Waist and Hip Circumferences 
and Risk of Barrett’s Esophagus 
 
  No. of 
studies 
OR (95% CI)a I2 ORb (95% CI) I2 ORc (95% 
CI) 
I2 
Barrett’s esophagus vs population-based controls      
 Waist circumference        
 Tertile 1 7 Referent  Referent  Referent  
 Tertile 2 7 1.34 (1.06-1.69) 37% 1.37 (1.04-
1.80) 
51% 1.53 (1.13-
2.07) 
45% 
 Tertile 3 7 1.88 (1.19-2.98) 85% 1.83 (1.12-
2.97) 
85% 2.18 (1.35-
3.51) 
68% 
 Per 5 cm 
increase 
7 1.09 (1.02-1.18) 88% 1.08 (1.01-
1.15) 
82% 1.18 (1.06-
1.31) 
75% 
 Hip circumference        
 Tertile 1 7 Referent  Referent  Referent  
 Tertile 2 7 1.05 (0.88-1.25) 0% 1.08 (0.90-
1.29) 
0% 0.83 (0.67-
1.03) 
0% 
 Tertile 3 7 1.28 (0.85-1.93) 82% 1.32 (0.86-
2.01) 
81% 0.75 (0.58-
0.98) 
4% 
 Per 5 cm 
increase 
7 1.04 (0.97-1.12) 75% 1.05 (0.97-
1.13) 
76% 0.88 (0.81-
0.96) 
42% 
Barrett’s esophagus vs GERD controls      
 Waist circumference        
 Tertile 1 6 Referent  Referent  Referent  
 Tertile 2 6 1.17 (0.97-1.41) 0% 1.15 (0.95-
1.40) 
0% 1.24 (0.99-
1.55) 
0% 
 Tertile 3 6 1.53 (1.28-1.83) 0% 1.46 (1.22-
1.76) 
0% 1.57 (1.21-
2.04) 
0% 
 Per 5 cm 
increase 
6 1.08 (1.05-1.11) 0% 1.06 (1.03-
1.09) 
0% 1.09 (1.02-
1.16) 
38% 
 Hip circumference        
 Tertile 1 6 Referent  Referent  Referent  
 Tertile 2 6 0.99 (0.83-1.19) 0% 0.94 (0.78-
1.14) 
0% 0.79 (0.64-
0.99) 
0% 
 Tertile 3 6 1.27 (1.00-1.61) 40% 1.31 (0.98-
1.76) 
56% 0.93 (0.60-
1.43) 
57% 
 Per 5 cm 
increase 
6 1.02 (0.99-1.06) 0% 1.05 (1.00-
1.09) 
25% 0.97 (0.87-
1.08) 
62% 
aUnadjusted models. 
bModels included terms for age (<50, 50-<60, 60-<70, 70+), sex (except NDB), education (except UNC and 
Cleveland), smoking (ever, never; except Cleveland) and either waist circumference or hip circumference. 
cModels adjusted for same factors as (b) but also waist circumference and hip circumference. 
CI, confidence interval; OR, odds ratio; GERD, gastroesophageal reflux disease.
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Table 4 Fully Adjusted Odds Ratios and 95% Confidence Intervals for the Associations Between Waist and 
Hip Circumferences and Risk of Barrett’s Esophagus, Stratified by Sex 
 
  Males Females 
  No. of 
studies 
OR (95% CI) I2 No. of 
studies 
OR (95% CI) I2 
Barrett’s esophagus vs population-based controls     
Waist circumference  No. of 
studies 
OR (95% CI) I2 No. of 
studies 
OR (95% CI) I2 
 Tertile 1 7 Referent  5 Referent  
 Tertile 2 7 1.41 (1.09-1.84) 14% 5 1.10 (0.44-2.78) 63% 
 Tertile 3 7 2.07 (1.32-3.25) 55% 4 1.89 (0.70-5.09) 44% 
Per 5 cm increase  7 1.18 (1.05-1.32) 72% 5 1.20 (0.97-1.48) 70% 
      
Hip circumference      
 Tertile 1 7 Referent  5 Referent  
 Tertile 2 7 0.86 (0.66-1.11) 12% 5 0.65 (0.25-1.71) 58% 
 Tertile 3 7 0.68 (0.48-0.98) 33% 5 0.97 (0.29-3.25) 68% 
Per 5 cm increase  7 0.85 (0.76-0.96) 54% 5 0.93 (0.74-1.16) 58% 
   
Barrett’s esophagus vs GERD controls  
Waist circumference  No. of 
studies 
OR (95% CI) I2 No. of 
studies 
OR (95% CI) I2 
 Tertile 1 6 Referent  4 Referent  
 Tertile 2 6 1.20 (0.93-1.55) 0% 4 1.17 (0.64-2.17) 23% 
 Tertile 3 6 1.57 (1.17-2.12) 0% 4 1.22 (0.67-2.22) 0% 
Per 5 cm increase  6 1.10 (1.03-1.17) 13% 5 1.02 (0.90-1.15) 26% 
      
Hip circumference      
 Tertile 1 6 Referent  4 Referent  
 Tertile 2 6 0.82 (0.63-1.05) 0% 4 0.82 (0.45-1.48) 24% 
 Tertile 3 6 0.94 (0.62-1.43) 40% 4 1.00 (0.54-1.84) 0% 
Per 5 cm increase  6 0.96 (0.86-1.07) 34% 5 1.04 (0.85-1.28) 58% 
NOTE. Models included terms for age (<50, 50-<60, 60-<70, 70+), education (except UNC and Cleveland), 
smoking (ever, never; except Cleveland), waist circumference and hip circumference.  
NDB and Houston were excluded from Female-only analyses. 
CI, confidence interval; OR, odds ratio; GERD, gastroesophageal reflux disease.
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Table 5 Fully Adjusted Odds Ratios and 95% Confidence Intervals for the Associations Between Waist 
and Hip Circumferences and Risk of Barrett’s Esophagus, Stratified by GERD symptoms 
 
   Barrett’s esophagus vs population-based controls 
  Less than weekly GERD 
symptoms 
At least weekly  
GERD symptoms 
  No. of 
studies 
OR (95% CI) I2 No. of 
studies 
OR (95% CI) I2 
Waist 
circumference 
       
 Tertile 1 6 Referent  6 Referent  
 Tertile 2 6 1.65 (1.12-2.44) 0% 6 1.22 (0.67-2.22) 52% 
 Tertile 3 6 2.15 (1.33-3.48) 0% 6 1.19 (0.58-2.44) 55% 
Per 5 cm increase  6 1.16 (1.06-1.28) 6% 6 1.06 (0.92-1.22) 56% 
        
Hip circumference        
 Tertile 1 6 Referent  6 Referent  
 Tertile 2 6 0.73 (0.50-1.07) 0% 6 0.86 (0.58-1.29) 0% 
 Tertile 3 6 0.66 (0.42-1.05) 0% 6 0.71 (0.44-1.13) 0% 
Per 5 cm increase  6 0.83 (0.73-0.95) 6% 6 0.90 (0.78-1.04) 22% 
NOTE. Models included terms for age (<50, 50-<60, 60-<70, 70+), sex (except NDB), education 
(except UNC and Cleveland), smoking (ever, never; except Cleveland), waist circumference and hip 
circumference. 
CI, confidence interval; OR, odds ratio; GERD, gastroesophageal reflux disease. 
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Study population 
We used data from eight independent case-control studies participating in BEACON: the Study of Digestive 
Health (based in Brisbane, Australia)16; the Factors Influencing the Barrett’s/Adenocarcinoma Relationship 
(FINBAR) study (based in Ireland)17; the Epidemiology and Incidence of Barrett’s Esophagus study (based in 
the Kaiser Permanente Northern California population)18; the Study of Reflux Disease (based in western 
Washington State)19; the Epidemiologic Case-Control Study of Barrett’s Esophagus (based at The University of 
North Carolina at Chapel Hill, NC); the Houston Barrett’s Esophagus study (based at the Michael E. DeBakey 
VA Medical Center at Houston, TX)20; The Newly Diagnosed Barrett’s Esophagus Study (based at the 
University of Michigan and Ann Arbor Veterans Affairs Medical Center at Ann Arbor, MI)11, and the Cleveland 
Barrett’s Esophagus Study (based at two hospitals in the Case Comprehensive ancer Center at Cleveland, 
OH: University Hospitals Case Medical Center and Cleveland Clinic Foundation)21.
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Supplementary Table 1 Adjusted Odds Ratios and 95% confidence intervals for the associations between 
waist and hip circumferences and risk of Barrett’s esophagus with and without adjusting for frequency of 
GERD symptoms, compared with population-based controls 
 
  No. of 
studies 
ORa (95% CI) I2 ORb (95% CI) I2 
Waist circumference      
 Tertile 1 6 Referent  Referent  
 Tertile 2 6 1.37 (1.08-1.74) 9% 1.47 (1.04-2.09) 43% 
 Tertile 3 6 1.68 (1.28-2.22) 4% 1.60 (1.12-2.30) 21% 
 Per 5 cm increase 6 1.14 (1.04-1.24) 63% 1.10 (1.01-1.21) 52% 
Hip circumference      
 Tertile 1 6 Referent  Referent  
 Tertile 2 6 0.86 (0.69-1.08) 0% 0.85 (0.65-1.10) 0% 
 Tertile 3 6 0.78 (0.58-1.04) 11% 0.73 (0.53-1.00) 0% 
 Per 5 cm increase 6 0.89 (0.81-0.99) 46% 0.89 (0.81-0.97) 8% 
NOTE. Cleveland was excluded due to missing data on GERD symptoms for controls. 
aModels included terms for age (<50, 50-<60, 60-<70, 70+), sex (except NDB), education, smoking (ever, 
never), waist circumference and hip circumference. 
bModels adjusted for same factors as (a) but also frequency of GERD symptoms (less than weekly, at least 
weekly). 
CI, confidence interval; OR, odds ratio; GERD, gastroesophageal reflux disease.
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Supplementary Table 2 Adjusted Odds Ratios and 95% confidence intervals 
for the associations of combinations of waist and hip circumferences and risk of 
Barrett’s esophagus in males, compared with population-based controls 
 
 Waist circumference 
 Tertile 1 Tertile 2 Tertile 3 
Hip circumference    
 Tertile 1 Referent 1.23 (0.86-1.76) 2.06 (0.93-4.57) 
 Tertile 2 0.80 (0.54-1.18) 1.23 (0.95-1.60) 1.46 (1.02-2.08) 
 Tertile 3 0.65 (0.21-2.06) 0.87 (0.54-1.38) 1.47 (0.90-2.42) 
NOTE. Models included terms for age (<50, 50-<60, 60-<70, 70+), education 
(except UNC & Cleveland), and smoking (ever, never; except Cleveland). 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
Supplementary Figure 1 Forest plot of the association between increasing tertiles of hip 
circumference and risk of Barrett’s esophagus compared with population-based controls. 
Models included terms for age (<50, 50-<60, 60-<70, 70+), sex, education (except 
Cleveland), smoking (ever, never; except Cleveland), waist circumference and hip 
circumference. Participating studies: Houston, the Houston Barrett’s Esophagus study; 
Cleveland, the Cleveland Barrett’s Esophagus Study(Case Comprehensive Cancer Center: 
University Hospitals Case Medical Center and Cleveland Clinic Foundation); FINBAR, the 
Factors Influencing the Barrett’s/Adenocarcinoma Relationship study (Ireland); KPNC, the 
Epidemiology and Incidence of Barrett’s Esophagus study (Kaiser Permanente, Northern 
California); NDB, The Newly Diagnosed Barrett’s Esophagus Study (University of Michigan 
and Ann Arbor Veterans Affairs Medical Center, Michigan); SDH, the Study of Digestive 
Health (Brisbane, Australia); and Washington, the Study of Reflux Disease (western 
Washington State). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
